頁籤選單縮合
題 名 | Immune Intervention with Monoclonal Antibodies Targeting CD152 (CTLA-4) for Autoimmune and Malignant Diseases=利用各種抗CD152單株抗體進行自體免疫及惡性腫瘤免疫治療的探討 |
---|---|
作 者 | 金立德; 朱紀實; 陳翰民; 王定偉; 廖順奎; | 書刊名 | 長庚醫學 |
卷 期 | 31:1 2008.01-02[民97.01-02] |
頁 次 | 頁1-15 |
分類號 | 414.82 |
關鍵詞 | 抗CD152抗體; 調控性T細胞; 自體免疫; 癌症; 免疫治療; Anti-CD152 antibodies; Treg; Autoimmunity; Cancer; Immunotherapy; |
語 文 | 英文(English) |
英文摘要 | CD152 or cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential receptor involved in the negative regulation of T cell activation. Because of its profound inhibitory role, CD152 has been considered a sound susceptible candidate in autoimmunity and a persuasive target for cancer immunotherapy for over a decade. However, the precise roles played by this molecule continue to emerge. In particular, recent evidence suggests that CD152 is also important in the homeostasis and function of a population of suppressive cells, termed regulatory T cells (Treg). In this review, we discuss the recent progress and main features of monoclonal antibodies (mAbs) targeting CD152 and examine how each mAb prepared to a distinct epitope may impact differently upon CD152 modulation depending on its demonstrated regulatory role acting as an agonist, antagonist, or inverse agonist. |
本系統中英文摘要資訊取自各篇刊載內容。